Drug Type Shared antigen vaccine, Therapeutic vaccine, Genetically engineered subunit vaccine |
Synonyms GSK 2241658A Antigen-Specific Cancer Immunotherapeutic, GSK Biologicals' 2241658A Antigen-Specific Cancer Immunotherapeutic, NY-ESO-1 Antigen Specific Cancer Immunotherapeutic + [7] |
Target |
Action modulators |
Mechanism NY-ESO-1 modulators(Cancer/testis antigen 1 modulators) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic melanoma | Phase 1 | Australia | 31 Jan 2011 | |
Metastatic melanoma | Phase 1 | Austria | 31 Jan 2011 | |
Metastatic melanoma | Phase 1 | France | 31 Jan 2011 | |
Metastatic melanoma | Phase 1 | Germany | 31 Jan 2011 | |
Metastatic melanoma | Phase 1 | Italy | 31 Jan 2011 | |
Metastatic melanoma | Phase 1 | Netherlands | 31 Jan 2011 | |
Metastatic melanoma | Phase 1 | Switzerland | 31 Jan 2011 | |
Metastatic melanoma | Phase 1 | United Kingdom | 31 Jan 2011 |
Phase 1 | 33 | jcvaiuertg = nywqolrfnr goovifjcuv (qnwlvyfhhx, ralxweeawo - nmwsibuueo) View more | - | 09 Oct 2019 |